(Reuters) – The $26,500-per-year price tag for Eisai Co Ltd and Biogen Inc’s newly approved Alzheimer’s disease drug is slightly above expectations, but should not dent demand for the promising …
Eisai
-
-
(Reuters) – Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer’s drug …
-
(Reuters) – The U.S. Food and Drug Administration on Friday approved Eisai Co Ltd and Biogen Inc’s Alzheimer’s drug lecanemab for the treatment of early forms of the fatal, brain-wasting …
-
By Deena Beasley and Julie Steenhuysen SAN FRANCISCO (Reuters) – Japan’s Eisai Co plans to seek full approval of its experimental Alzheimer’s drug lecanemab in the United States, Europe and …
-
Biogen, and its Japanese partner Eisai, announced Monday that it plans to begin the process for U.S. approval for its experimental drug for Alzheimer’s. Biogen and Eisai announced “rolling submission” …